CTRI/2021/06/034069已完成4 期
A prospective, multicenter, open label, phase IV study to evaluate safety and efficacy of Adapalene 0.3% - Benzoyl peroxide 2.5% gel in subjects with Moderate to Severe Acne Vulgaris.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 122
- 试验地点
- 6
- 主要终点
- To evaluate Safety and tolerability of Adapalene 0.3% - Benzoyl peroxide 2.5% gel for treatment of Moderate to Severe Acne Vulgaris by assessing below parameters:
研究概览
简要总结
It is a phase IV clinical study which involves the collection of clinical data to evaluate the safety and effectiveness of Adapalene 0.3% - Benzoyl peroxide 2.5% gel in subjects with Moderate to Severe Acne Vulgaris
Acne vulgaris is a disorder of the pilosebaceous gland occurring usually at puberty but can also be seen in adult age.[1] The disease characterized by the formation of open and closed comedones (non-inflammatory lesions), papules, pustules, and nodulocystic lesions (inflammatory lesions).
Hence this clinical phase IV studies will be done just to verify the safety and effectiveness of Adapalene 0.3% - Benzoyl peroxide 2.5% gel in subjects with Moderate to Severe Acne Vulgaris.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 12.00 Year(s) 至 40.00 Year(s)（—）
- 性别
- All
入选标准
- •1 Male or female subject of at least 12 years old up to 40 years of age inclusive.
- •2.Subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined by: b.
- •A minimum of 25-100 inflammatory lesions (papules and pustules); and c.
- •A minimum of 30-150 non-inflammatory lesions (open and closed comedones) in total (excluding the nose); and d.No more than two acne nodules (≥ 1 cm) 3.Female subjects of childbearing potential must have a negative urine pregnancy test (UPT) at Baseline visit (Visit 1) 4.Female subjects of childbearing potential must practice an effective method of contraception during the clinical trial and at least 1 month after the last clinical trial treatment application: medical contraception [combined oral contraceptives (estrogens and progesterone) or implanted or injectable contraceptives with stable dose for 1 month prior to clinical trial entry, bilateral tubal ligation, hormonal Intra-Uterine Device (IUD) inserted at least 1 month prior to clinical trial entry, strict abstinence (1 month prior to trial entry and agrees to continue for the duration of the trial), condom with spermicide, vasectomized partner (for at least 3 months prior to clinical trial entry) 5.Females of non-childbearing potential, e.g. Premenses, Post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy, or bilateral oophorectomy.
- •6.Subject having read, understood and signed the approved Informed Consent Form (ICF) prior to any participation in the clinical trial.
- •Subject under the age of 18 having signed an assent Form to participate in the clinical trial and their parent(s) or legal representative having read and signed the informed consent form prior to any clinical trial related procedure 7.Subject willing and able to comply with the requirements of the trial protocol, in particular, subject must adhere to the visit schedule, concomitant therapy prohibitions, and must be compliant to the treatment 8.Subject must be willing to be photographed.
- •Subject (and parents/guardian if subject is under18 years of age) must be willing to consent for the same.
排除标准
- •1.Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodule cystic acne, acne requiring systemic treatment, 2.Subject with history of lupus, atopic dermatitis, perioral dermatitis, dermatomyositis, rosacea on the face 3.Prior failure to treatment with Adapalene 0.3%.
- •BPO 2.5% Gel 4.Subject with damaged facial skin (e.g. tattoo, cuts, skin abrasion, eczema or sunburned skin) 5.Female subject who is pregnant, lactating or planning a pregnancy during the trial 6.Subject with known impaired hepatic or renal functions, 7.Subject with a wash-out period for topical treatment or procedures on the face less than: Topical treatments: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone, hydroxy acids, Zinc containing treatments, , antiseptics, other anti-inflammatory products or other acne treatments (for example salicylic acid treatments/ transdermal contraceptives are forbidden if used to treat acne)2 weeks Retinoids 4 weeksCosmetic/aesthetic procedures on the face (e.g., comedones extraction, desquamating, or abrasive agents, adhesive cleansing strips) 1 week Wax epilation 2 weeks Photodynamic therapy 6 weeks Laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne 3 months. 8.Subject with a wash-out period for systemic treatment less than: Corticosteroids, (except locally acting corticosteroids such as inhaled or intrathecal or dermal application at distance from the face), tetracyclines, other antibiotics (except penicillin) 1 month Oral retinoids/isotretinoin/ anti-androgens / Cyproterone acetate / Chlormadinone acetate 6 months Spironolactone/ Drospirenone (except if at a stable dose for at least 3 months for drospirenone) 3 months Immunomodulators 3 months Oral contraceptives/ oral dapsone for acne 1 month 9.Subject with active or chronic skin allergies, 10.Subject with known or suspected allergy to the investigational product 11.Subject who has used tanning booths or lamps or had excessive ultraviolet (UV) radiation exposure within 1 month prior to clinical trial entry or foresees intensive UV exposure during the trial (mountain sports, sailing, sunbathing, etc.), 12.Subject who is at risk in terms of precautions, warnings, and contraindications Subjects with active infection who needs administration of antibiotics 13.Subject with a beard or other facial hair that might interfere with trial assessments. 14.Subject with an acute / chronic disease, uncontrolled systemic disease or a history of major medical or psychiatric condition or surgical interventions that, in the opinion of the investigator, might put the subject at risk. 15.Subject under guardianship, hospitalized subject in a public or private institution for a reason other than the research, and subject deprived of his/her freedom, 16.Subject who has participated in another investigational product or device research trial within 30 days prior to enrolment 17.Subject who is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
结局指标
主要结局
To evaluate Safety and tolerability of Adapalene 0.3% - Benzoyl peroxide 2.5% gel for treatment of Moderate to Severe Acne Vulgaris by assessing below parameters:
时间窗: Baseline, Week 2, Week 8 & Week 12
Endpoint: Local tolerance: Raw value at each visit and worst-score across visit, % of Subjects across scores at each post-baseline visit
时间窗: Baseline, Week 2, Week 8 & Week 12
•Adverse Events throughout the trial
时间窗: Baseline, Week 2, Week 8 & Week 12
Endpoint: Incidence of adverse events throughout the trial
时间窗: Baseline, Week 2, Week 8 & Week 12
次要结局
- •Mean percent change in lesion counts (inflammatory and non-inflammatory) will be assessed(oInflammatory lesions: papules and pustules)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
4 期
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as Infimabâ„¢ in patients with moderate to severe plaque psoriasis which is a skin disease characterized by raised red patches covered with a silvery white buildup of dead skincells or scaleCTRI/2019/09/021078Reliance Life Sciences Pvt Ltd200
进行中（未招募）
4 期
A study to evaluate the safety and efficacy of Dienogest in patients suffering from endometriosisCTRI/2020/10/028556Jagsonpal Pharmaceuticals Limited200
招募中
4 期
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.End Stage Renal Disease (ESRD)NCT06597201Chengdu Qingshan Likang Pharmaceutical Co., Ltd400
招募中
4 期
A study to assess the safety and efficacy of fixed dose combination of Montelukast 10 mg plus Acebrophylline SR 200 mg tablet in patients having bronchial asthmaCTRI/2020/02/023237Sun Pharma Laboratories Limited206
已完成
4 期
A clinical study to see the effect and safety of Phenocaine Plus Injection in Cataract Surgery.CTRI/2021/04/032545Entod Pharmaceuticals Ltd219